Medtronic says a study of its InterStim neurostimulation device shows it's better than medication alone for treating less-severe overactive bladder syndrome.
Medtronic  (NYSE:MDT ) is touting positive results from a study of its InterStim sacral nerve stimulator for treating less-severe overactive bladder syndrome, saying the device produces "superior efficacy and quality of life" compared with medication alone.
The Fridley, Minn.-based medical device company's InSite study found that 61% of patients treated with the device reported "significant improvement" in OAB symptoms, defined as ≥50% improvement in average leaks/day, ≥50% improvement in voids/day or a return to normal voiding frequency of less than 8 voids each day. That compares with 42% of patients who reported similar improvement after standard medical treatment.
The study, results from which were presented at the American Urogynecologic Society's annual meeting in Chicago yesterday, also showed improvement for patients with urinary urge incontinence who received the InterStim therapy. Seventy-one percent of those patients reported improvement, versus only 47% of the standard medical treatment cohort. Complete urinary continence was reported in 40% of the InterStim arm of the trial, compared with just 21% of the control arm.